中国药品曾因缺乏权威认证的国际价格信息，导致海外市场难以找到可靠的定价依据。为此，国家医保 局发起建设中国药登系统，由北京药品登记信息服务有限公司作为运营主体，2025年12月2日上线运 行。其核心功能是为企业提供权威、规范、透明的市场价格登记查询服务。药品上市许可持有人可获取 登记价格多语种查询凭证，作为权威价格证明。 中国药登系统自上线以来，网站日活跃用户已超过万人次。截至目前，该系统申请注册药品企业达60 家，覆盖全国18个省份；登记22个药品，包括中成药、化药、生物制药等类型。北京药品价格登记信息 服务有限公司总经理李克斌说："系统将持续完善服务，计划推动与国际主流机构的互认合作，进一步 简化中国药械产品进入海外市场的流程，助力中国医药创新成果走向世界。" （来源：千龙网） 帮助我国药品企业"明码实价"走向国际市场的平台——中国药品价格登记系统，上线一个半月服务全国 18个省份的60家企业，登记22个药品。 ...

Core Viewpoint - The launch of the drug price registration system in China is a significant step towards establishing a global pricing framework for innovative drugs, enhancing the international competitiveness of Chinese pharmaceutical companies [1][3][6]. Group 1: Drug Price Registration System - The drug price registration system, initiated by the National Healthcare Security Administration, allows domestic and foreign pharmaceutical companies to independently declare drug prices, creating a comprehensive pricing archive [1][3]. - The system operates independently from provincial procurement platforms and follows principles of "one location acceptance, nationwide sharing, and global openness," which aids in building a globalized drug pricing system [1][3]. - The registration of prices does not alter the medication costs for insured and uninsured individuals [1]. Group 2: Support for Chinese Pharmaceutical Companies - The new system addresses the shortcomings in the pricing mechanism for innovative drugs, facilitating their entry into international markets and allowing for pricing that aligns with local payment systems [3][4]. - Companies like Yifan Pharmaceutical highlight that the system will provide substantial support for overseas expansion, allowing for a more accurate reflection of the true value of innovative drugs [4]. - The system enables companies to register prices according to international practices, providing verifiable pricing information to regulatory bodies and partners [4]. Group 3: Attracting Foreign Innovative Drugs - The establishment of the drug price registration system is expected to attract more high-quality foreign innovative drugs into the Chinese market, as multinational companies will be encouraged to participate in national healthcare negotiations [6][7]. - The system allows multinational companies to register prices independently in China, creating a clear distinction between market supply prices and negotiated healthcare prices, which enhances the certainty of market entry for innovative drugs [7].